About alk abello as - AKBLF
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.
AKBLF At a Glance
ALK-Abello A/S
Bøge Allé 6-8
Hørsholm, Capital Region 2970
| Phone | 45-45-74-75-76 | Revenue | 954.48M | |
| Industry | Pharmaceuticals: Major | Net Income | 181.01M | |
| Sector | Health Technology | 2025 Sales Growth | 18.866% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,721 | |
| View SEC Filings |
AKBLF Valuation
| P/E Current | 46.454 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 43.992 |
| Price to Sales Ratio | 8.353 |
| Price to Book Ratio | 7.859 |
| Price to Cash Flow Ratio | 29.02 |
| Enterprise Value to EBITDA | 26.185 |
| Enterprise Value to Sales | 8.218 |
| Total Debt to Enterprise Value | 0.008 |
AKBLF Efficiency
| Revenue/Employee | 350,783.833 |
| Income Per Employee | 66,522.219 |
| Receivables Turnover | 4.533 |
| Total Asset Turnover | 0.713 |
AKBLF Liquidity
| Current Ratio | 3.381 |
| Quick Ratio | 2.04 |
| Cash Ratio | 0.933 |
AKBLF Profitability
| Gross Margin | 65.875 |
| Operating Margin | 26.347 |
| Pretax Margin | 25.903 |
| Net Margin | 18.964 |
| Return on Assets | 13.528 |
| Return on Equity | 20.575 |
| Return on Total Capital | 16.773 |
| Return on Invested Capital | 19.277 |
AKBLF Capital Structure
| Total Debt to Total Equity | 6.486 |
| Total Debt to Total Capital | 6.091 |
| Total Debt to Total Assets | 4.557 |
| Long-Term Debt to Equity | 5.508 |
| Long-Term Debt to Total Capital | 5.173 |